ストックスクリーナーアプリを入手
61.39
1.35%
0.82
アフターアワーズ：
61.99
0.60
+0.98%
Bristol Myers Squibb Co (BMY) 最新ニュース
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook - Zacks Investment Research
Bristol Myers Squibb beats forecasts and nudges up sales outlook - MedWatch
Bristol Myers Raises Sales Guidance on Demand For New Drugs - Bloomberg.com
Bristol Myers lifts sales outlook as newer medicines grow - The Pharma Letter
Bristol-Myers Squibb Q3 2026 Earnings Call Transcript - Benzinga
Bristol Myers Squibb (BMY) Raises 2026 Revenue Outlook After Str - GuruFocus
Bristol-Myers Squibb Reports Q3 2026 Revenue of $13.1 Billion an - GuruFocus
BRISTOL-MYERS SQUIBB ($BMY) Releases Q3 2026 Earnings - Quiver Quantitative
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 - Finviz
Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 29 - StreetInsider
Bristol Myers: Q3 Earnings Snapshot - kare11.com
86,136 Bristol Myers Squibb Company $BMY Shares Sold by Conning Inc. - MarketBeat
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Bristol-Myers Squibb earnings loom as pipeline takes center stage - Investing.com
Pathos raises $237M and lands Alzheimer’s drug deal with Tempus, Bristol Myers - Crain's Chicago Business
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? - Zacks Investment Research
Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters - The Motley Fool
3 Cheap Dividend Stocks I'd Buy Without Any Hesitation - The Motley Fool
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? - Zacks Investment Research
Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors - ChartMill
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study - BioSpace
Bristol Myers Iza-Bren Phase 3 PFS Reaches 11.1 Months - grafa.com
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Pathos AI Raises $237M at $3B Valuation in Round Led by Bristol Myers Squibb - citybiz
3 High-Yield Stocks to Buy With $1,000 Right Now - The Motley Fool
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? - The Motley Fool
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy - GlobeNewswire Inc.
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie - GlobeNewswire Inc.
Bristol Myers Squibb Co. CDR Overview (BMY) - Barron's
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial - STAT
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol Myers discloses patient death in early-stage cell therapy study - Reuters
What's Going On with Bristol Myers Squibb Stock on Friday? - Benzinga
Bristol Myers Reports CAR-T Death as Safety Concerns Mount - Bloomberg.com
Bristol-Myers Squibb Co: Following Data Cutof - Moomoo
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? - Zacks Investment Research
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development - Reuters
Bristol Myers, SystImmune breast cancer drug cuts progression risk in study - Reuters
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? - The Motley Fool
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? - The Motley Fool
Bristol-Myers Squibb Company (BMY) Options ChainYahoo Finance - Yahoo! Finance Canada
IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials - BioSpace
A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Va - GuruFocus
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue - The Motley Fool
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
2.11%
0.12%
大文字化:
|
ボリューム (24 時間):